---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338021"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2026-08-06T20:11:43+00:00"
generated_at: "2026-08-06T20:15:58.314703+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q2 net loss $198.8M; MYQORZO revenue $25M; ACACIA-HCM positive

## Summary
- Total revenues $28.6M (Q2 2025: $66.8M) including $25.3M MYQORZO net product revenue; no license/milestone revenue in Q2 2026.
- Net loss $198.8M ($1.50/share) vs $134.4M ($1.12) in Q2 2025; R&D $97.8M, SG&A $104.4M.
- Cash, equivalents and investments $1.7B (up from $1.1B at Mar 31, 2026) after $760.1M net from public offering of 11.3M shares at $71.
- ACACIA-HCM (nHCM) met dual primary endpoints; supplemental NDA for aficamten in nHCM expected Q4 2026.
- FY 2026 GAAP combined R&D+SG&A guidance raised to $860M-$890M from $830M-$870M; over 700 prescribers, ~1,500 patients dispensed MYQORZO.

## SEC filing metadata
- accession: 0001193125-26-338021
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2026-08-06T20:11:43+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/0001193125-26-338021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338021
- JSON: https://secwatch.observer/filing/0001193125-26-338021.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.